bs-16249R [Primary Antibody]
GLIS3 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: GLIS3

Immunogen Range: 101-200/775


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 169792

Swiss Prot: Q8NEA6

Source: KLH conjugated synthetic peptide derived from human GLIS3

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Background:

Acts as both a repressor and activator of transcription. Binds to the consensus sequence 5'-GACCACCCAC-3' (By similarity).

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
FCM(1:20-100)
IHC-P(1:200-400)

Predicted Molecular Weight: 84


Cross Reactive Species: Human
Rat
Sheep

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Zhuohang Liu. et al. GLIS Family Zinc Finger 3 Promoting Cell Malignant Behaviors and NF-B Signaling in Glioma. Brain Res. 2021 Aug;:147623Read more>>
  • Hong-Bo YANG. et al. The compensatory increase of GLIS3 inhibited neuronal apoptosis through regulating MOB1b: a possible strategy for the functional recovery after spinal cord injury. EXP ANIM TOKYO. 2023 Aug 12Read more>>
VALIDATION IMAGES

Formalin-fixed and paraffin embedded rat kidney labeled with Rabbit Anti-GLIS3 Polyclonal Antibody, Unconjugated (bs-16249R) at 1:200 followed by conjugation to the secondary antibody and DAB staining


Formalin-fixed and paraffin embedded human kidney labeled with Rabbit Anti-GLIS3 Polyclonal Antibody, Unconjugated (bs-16249R) at 1:200 followed by conjugation to the secondary antibody and DAB staining


Lane 1: Human U251 cell lysates; Lane 2: Human U87MG cell lysates; Lane 3: Human A549 cell lysates; Lane 4: Human 293T cell lysates; Lane 5: Human MDA-MB-231 cell lysates probed with GLIS3 Polyclonal Antibody, Unconjugated (bs-16249R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.